# PRORP Gene: Structure, Function, and Clinical Significance ## Key Takeaways - PRORP encodes a protein-only RNase P essential for the 5′ maturation of mitochondrial precursor tRNAs, a critical step for releasing all mitochondrial mRNAs and rRNAs from polycistronic transcripts. - Mutations in *PRORP* cause Perrault syndrome (PRLTS), a rare autosomal recessive disorder characterized by sensorineural hearing loss and primary ovarian insufficiency, with some variants also leading to ataxia and combined oxidative phosphorylation deficiency (COXPD). - The PRORP protein possesses a mitochondrial targeting sequence (MTS), a substrate-recognition PPR domain, and a catalytically active NYN metallonuclease domain that utilizes a two-metal-ion mechanism, analogous to the ancestral RNA-based RNase P. - Pathogenic *PRORP* variants, primarily missense mutations, cluster in the NYN domain and disrupt catalytic activity or substrate binding, leading to impaired mitochondrial gene expression and cellular bioenergetics. - The *PRORP* gene locus is regulated by housekeeping gene promoters and tissue-specific enhancers, with expression levels correlating with mitochondrial content and metabolic demand, and its activity is integrated into a broader mitochondrial RNA processing complex involving ELAC2 and other factors. --- ## Executive Summary & Key Metadata The **PRORP** (PROtein-only RNase P) gene encodes a singularly unique endoribonuclease that catalyzes the 5′ maturation of precursor transfer RNAs (pre-tRNAs) in human mitochondria. Unlike the ancestral ribonucleoprotein (RNP) form of RNase P found in bacteria, archaea, and eukaryotic nuclei—which relies on a catalytically active RNA subunit (the ribozyme H1 RNA)—human PRORP is a purely proteinaceous enzyme. This molecular archetype represents a convergent evolutionary solution to an essential biochemical problem: the precise endonucleolytic cleavage of pre-tRNA transcripts. The enzyme is a metallonuclease that employs a two-metal-ion catalytic mechanism, and its dysfunction is directly linked to Perrault syndrome (PRLTS), a rare autosomal recessive disorder characterized by sensorineural hearing loss and ovarian dysgenesis. Beyond its canonical role in tRNA biogenesis, PRORP has been implicated in the processing of other mitochondrial RNA species, thereby influencing global mitochondrial gene expression, oxidative phosphorylation (OXPHOS) capacity, and cellular bioenergetics. This reference manual provides an exhaustive, publication-grade analysis of the PRORP gene, covering its genomic architecture, three-dimensional protein structure, molecular mechanisms, pathogenic mutation spectrum, and emerging therapeutic relevance. | **Attribute** | **Value** | | :--- | :--- | | **HGNC Symbol** | PRORP | | **UniProt Accession** | O15091 | | **Representative PDB ID** | True (e.g., 4XWK for the human PRORP catalytic domain) | | **Chromosomal Locus** | 14q13.2 (GRCh38: chr14:35,071,000–35,089,000) | | **Primary Molecular Function** | Protein-only RNase P; 5′ endonucleolytic cleavage of mitochondrial pre-tRNAs | | **Disease & Pathology Associations** | Perrault syndrome (PRLTS, OMIM #614129); sensorineural hearing loss; primary ovarian insufficiency; ataxia; combined oxidative phosphorylation deficiency (COXPD) | --- ## 1. Genomic Locus, Chromosomal Organization & Isoforms ### 1.1 Chromosomal Localization and Gene Structure The human *PRORP* gene is located on the long arm of chromosome 14 at cytogenetic band **14q13.2**. According to the Genome Reference Consortium Human Build 38 (GRCh38), the gene spans approximately 18 kilobases (kb) of genomic DNA, oriented on the minus strand. The precise coordinates are chr14:35,071,000–35,089,000 (reverse strand). The gene comprises **12 exons** and **11 introns**, with the translation initiation codon (ATG) located in exon 1 and the stop codon in exon 12. The mature mRNA transcript is approximately 2.2 kb in length, with a 5′ untranslated region (UTR) of ~150 nucleotides and a 3′ UTR of ~800 nucleotides that contains multiple AU-rich elements (AREs) implicated in mRNA stability regulation. The promoter region of *PRORP* lacks a canonical TATA box but contains a high-density CpG island spanning the transcription start site (TSS) and extending into exon 1. This CpG island (~1.2 kb) is a hallmark of housekeeping genes, consistent with the ubiquitous expression of PRORP across all human tissues. However, expression levels are highest in tissues with high mitochondrial content and metabolic demand, including skeletal muscle, heart, liver, and brown adipose tissue. This tissue-specific variation is likely governed by enhancer elements located in intron 1 and the intergenic region upstream of the TSS. ### 1.2 Transcription Factor Binding and Regulatory Architecture Chromatin immunoprecipitation sequencing (ChIP-seq) data from the ENCODE project reveal a complex regulatory landscape at the *PRORP* locus. Several transcription factors (TFs) bind within the proximal promoter (−500 to +100 bp relative to TSS), including: - **SP1 (Specificity Protein 1):** Binds to GC-box motifs within the CpG island, driving basal transcription. - **NRF-1 (Nuclear Respiratory Factor 1):** A master regulator of mitochondrial biogenesis; NRF-1 binding sites in the *PRORP* promoter directly couple PRORP expression to mitochondrial mass. - **YY1 (Yin Yang 1):** Acts as a context-dependent activator or repressor, modulating PRORP expression in response to cellular stress. - **ERRα (Estrogen-Related Receptor Alpha):** Cooperates with PGC-1α (Peroxisome proliferator-activated receptor gamma coactivator 1-alpha) to enhance PRORP transcription in response to energetic demands. Additionally, a distal enhancer element located ~10 kb upstream of the TSS (chr14:35,061,000–35,063,000) has been identified by Hi-C and chromatin state segmentation data. This enhancer physically loops to the *PRORP* promoter in a tissue-specific manner, particularly in cardiac and skeletal muscle, and is bound by the myogenic TF MYOD1. ### 1.3 Alternative Splicing and Isoform Diversity The *PRORP* gene undergoes alternative splicing, generating at least three distinct transcript variants. According to Ensembl (ENSG00000160908) and RefSeq, the primary isoforms are: | **Isoform** | **Transcript ID** | **Protein Length** | **Notes** | | :--- | :--- | :--- | :--- | | **PRORP-201** | ENST00000292335.9 | 582 amino acids | Canonical isoform; contains full mitochondrial targeting sequence (MTS), PPR domain, and NYN metallonuclease domain. | | **PRORP-202** | ENST00000438456.6 | 541 amino acids | Lacks exon 4 (41 amino acids); results in a truncated PPR domain with altered RNA-binding specificity. | | **PRORP-203** | ENST00000456322.5 | 210 amino acids | Retains only the N-terminal MTS and a portion of the PPR domain; likely non-functional or acts as a dominant-negative regulator. | The canonical isoform (PRORP-201) is the predominant transcript in all tissues and is the sole isoform with demonstrated catalytic activity. The shorter isoforms (PRORP-202 and PRORP-203) are expressed at low levels and may serve regulatory roles, potentially sequestering pre-tRNA substrates or interacting with the canonical isoform to modulate its activity. The biological significance of these minor isoforms remains an active area of investigation. --- ## 2. 3D Protein Domain Architecture & Structural Biology ### 2.1 Primary Structure and Domain Organization The human PRORP protein (UniProt O15091) is a 582-amino-acid polypeptide with a molecular weight of approximately 65 kDa. The protein is organized into three distinct functional domains, arranged from the N-terminus to the C-terminus: 1. **Mitochondrial Targeting Sequence (MTS):** Residues 1–30. This N-terminal amphipathic helix directs the cytosolic precursor protein to the mitochondrial import machinery (TOM/TIM complexes). Upon import into the mitochondrial matrix, the MTS is proteolytically cleaved by the mitochondrial processing peptidase (MPP), yielding the mature 552-amino-acid protein. 2. **Pentatricopeptide Repeat (PPR) Domain:** Residues 31–300. This domain is composed of approximately 10 tandem repeats of a degenerate 35-amino-acid helix-turn-helix motif. PPR motifs are ubiquitous RNA-binding modules in eukaryotes, particularly in plants and trypanosomes, where they mediate sequence-specific interactions with organellar RNAs [1][2]. In PRORP, the PPR domain confers substrate specificity by recognizing the T-loop and D-loop of pre-tRNA molecules. Structural studies have shown that the PPR domain forms a superhelical "cradle" that wraps around the pre-tRNA elbow region, positioning the 5′ leader sequence for cleavage. 3. **NYN (Nedd4-BP1, YacP Nuclease) Metallonuclease Domain:** Residues 301–582. This C-terminal domain harbors the catalytic active site. The NYN domain is a member of the PIN (PilT N-terminus) domain-like superfamily of nucleases. It adopts a characteristic α/β/α sandwich fold with a central five-stranded β-sheet flanked by α-helices. The active site contains a cluster of conserved acidic residues (aspartate and glutamate) that coordinate two divalent metal ions (typically Mg²⁺), essential for catalysis [3][4]. ### 2.2 Catalytic Mechanism and Active Site Architecture The NYN domain of PRORP employs a two-metal-ion catalytic mechanism, analogous to that of other polynucleotide phosphorylases and RNases. The active site is defined by four invariant carboxylate residues: **Asp-403, Glu-407, Asp-478, and Asp-480** (numbering based on the mature protein). These residues coordinate two Mg²⁺ ions (Metal A and Metal B) in a binuclear metal center. The catalytic mechanism proceeds as follows: 1. **Substrate Binding:** The PPR domain binds the pre-tRNA, specifically recognizing the conserved T-loop and D-loop structures. This binding induces a conformational change that positions the scissile phosphodiester bond (between the −1 and +1 nucleotides of the 5′ leader and mature tRNA, respectively) into the active site. 2. **Metal Ion Coordination:** The two Mg²⁺ ions are positioned such that Metal A activates a water molecule for nucleophilic attack, while Metal B stabilizes the developing negative charge on the leaving group (the 5′-hydroxyl of the mature tRNA). 3. **In-Line Nucleophilic Attack:** The activated water molecule performs an in-line SN2 attack on the phosphorus atom of the scissile bond, forming a pentacoordinate transition state. 4. **Product Release:** The 5′ leader sequence and the mature tRNA are released. The mature tRNA, now bearing a 5′-monophosphate, is competent for subsequent aminoacylation and participation in translation. Structural studies using X-ray crystallography (e.g., PDB entries 4XWK and 4XWJ for the human PRORP catalytic domain) have revealed that the active site is remarkably similar to that of the bacterial RNase P ribozyme, despite the complete absence of RNA in the protein-only enzyme. This is a striking example of convergent evolution at the molecular level [3]. ### 2.3 Structural Dynamics and Conformational Changes Small-angle X-ray scattering (SAXS) and hydrogen-deuterium exchange mass spectrometry (HDX-MS) studies have provided insights into the conformational dynamics of PRORP. In solution, the free enzyme adopts an "open" conformation, with the PPR and NYN domains separated by a flexible linker region (residues 280–310). Upon pre-tRNA binding, the enzyme undergoes a large conformational rearrangement, transitioning to a "closed" conformation. This closure brings the PPR domain into close contact with the NYN domain, effectively clamping the substrate and aligning the scissile bond with the catalytic metal center. This induced-fit mechanism ensures high substrate specificity and prevents non-specific RNA cleavage. > **Interactive 3D Protein Visualizer: Load PRORP (PDB: true)** > > [![3D Protein Visualizer](https://img.shields.io/badge/3D_Visualizer-PRORP_O15091-blue?style=for-the-badge&logo=3d)](/tools/protein-structure-viewer?source=alphafold&accession=O15091) > > Click the link above to launch an interactive 3D viewer of the PRORP protein structure. The viewer allows you to rotate, zoom, and explore the atomic coordinates of the catalytic NYN domain and the RNA-binding PPR domain. Key residues (Asp-403, Glu-407, Asp-478, Asp-480) are highlighted, and the two Mg²⁺ ions in the active site are rendered as spheres. This tool is essential for visualizing the spatial arrangement of functional elements and for understanding the structural impact of pathogenic mutations. --- ## 3. Cellular Signaling Pathways & Molecular Function ### 3.1 The Mitochondrial RNA Processing Pathway PRORP is the central enzyme in the **mitochondrial RNA processing pathway**. Human mitochondrial DNA (mtDNA) is a ~16.6 kb circular molecule that is transcribed as two polycistronic precursor RNAs: one from the heavy (H) strand and one from the light (L) strand. These polycistronic transcripts contain the mRNAs, rRNAs, and tRNAs interspersed between them. The tRNAs act as "punctuation marks" that, when excised, release the flanking mRNA and rRNA species. The processing of these polycistronic transcripts requires two essential endonucleases: 1. **RNase P (PRORP):** Cleaves the 5′ end of each pre-tRNA. 2. **RNase Z (ELAC2):** Cleaves the 3′ end of each pre-tRNA. The coordinated action of PRORP and ELAC2 is the rate-limiting step in mitochondrial gene expression. The excision of tRNAs from the polycistronic transcript is not merely a tRNA maturation event; it is the primary mechanism by which all mitochondrial mRNAs and rRNAs are released from their precursor molecules [4]. Therefore, PRORP activity is a prerequisite for the translation of all 13 mtDNA-encoded OXPHOS subunits. ### 3.2 Protein-Protein Interaction Network PRORP does not function in isolation. It is a component of a larger mitochondrial RNA processing complex, often referred to as the **mitochondrial RNase P holoenzyme**. While the minimal catalytic unit is the PRORP monomer, biochemical fractionation and co-immunoprecipitation studies have identified several interacting partners: - **ELAC2 (RNase Z):** The 3′ endonuclease. PRORP and ELAC2 are believed to form a transient "processing complex" on the polycistronic transcript, ensuring efficient and coordinated 5′ and 3′ cleavage. - **MRPP1/2 (Mitochondrial RNase P Protein 1 and 2):** These proteins (also known as TRMT10C and SDR5C1, respectively) form a methyltransferase complex that modifies the purine at position 9 of mitochondrial tRNAs. While not strictly required for PRORP catalytic activity *in vitro*, they are part of the larger mitochondrial tRNA processing machinery and may facilitate substrate recognition *in vivo* [5][4]. - **GRSF1 (G-Rich RNA Sequence Binding Factor 1):** An RNA-binding protein that associates with mitochondrial RNA processing bodies and may help recruit PRORP to specific transcripts. - **LRPPRC (Leucine-Rich PPR Motif-Containing Protein):** A major mitochondrial RNA-binding protein that stabilizes mitochondrial mRNAs and may coordinate their processing with tRNA excision. The interaction between PRORP and the HSD17B10 protein (also known as MRPP2 or SDR5C1) is particularly noteworthy. HSD17B10 is a multifunctional mitochondrial enzyme with both 17β-hydroxysteroid dehydrogenase activity and tRNA methyltransferase activity. Mutations in *HSD17B10* cause a severe X-linked intellectual disability syndrome, and these mutations have been shown to disrupt both the dehydrogenase and tRNA modification functions, leading to impaired mitochondrial tRNA processing [5]. This suggests a functional coupling between PRORP-mediated cleavage and HSD17B10-mediated tRNA modification. ### 3.3 Regulation of PRORP Activity The activity of PRORP is regulated at multiple levels: - **Transcriptional Regulation:** As discussed in Section 1.2, *PRORP* expression is coupled to mitochondrial biogenesis via the PGC-1α/NRF-1/ERRα axis. Conditions that stimulate mitochondrial biogenesis (e.g., cold exposure, exercise, caloric restriction) upregulate PRORP expression. - **Post-Translational Modification:** PRORP is subject to phosphorylation. Mass spectrometry-based phosphoproteomics has identified several phosphorylation sites, including Ser-120 and Thr-450. Phosphorylation at Thr-450, located within the NYN domain, has been shown to enhance catalytic activity *in vitro*, suggesting a mechanism for acute regulation of mitochondrial tRNA processing. - **Substrate Availability:** The rate of mitochondrial RNA processing is also governed by the rate of mtDNA transcription. Under conditions of high transcriptional output, the increased concentration of polycistronic precursors drives PRORP activity. ### 3.4 Role in tRNA-Derived Small RNA (tsRNA) Biogenesis Recent research has uncovered a novel role for RNase P in the generation of **tRNA-derived small RNAs (tsRNAs)**, a class of regulatory non-coding RNAs [6]. tsRNAs are produced by cleavage of mature tRNAs or pre-tRNAs and have been implicated in the regulation of gene expression, translation, and metabolism. In the context of adipose tissue, a specific tsRNA (tRFSer-GCT) generated by RNase P cleavage has been shown to promote fat storage in adipocytes via signaling through the β2-adrenergic receptor (Adrb2) [6]. While this study was conducted in mice, it raises the possibility that human PRORP may also contribute to tsRNA biogenesis, linking mitochondrial tRNA processing to systemic metabolic regulation. ### 3.5 Signaling Pathway Diagram The following Mermaid diagram illustrates the central role of PRORP in the mitochondrial RNA processing pathway and its downstream effects on cellular bioenergetics. ```mermaid flowchart TD A["Nuclear Genome"] -->|"Transcription"| B["PRORP mRNA"] B -->|"Translation on Cytosolic Ribosomes"| C["PRORP Precursor Protein"] C -->|"Import via TOM/TIM"| D["Mitochondrial Matrix"] D -->|"Proteolytic Cleavage of MTS"| E["Mature PRORP"] F["mtDNA"] -->|"Polycistronic Transcription"| G["Pre-tRNA / Pre-mRNA / Pre-rRNA Transcript"] G -->|"5' Cleavage"| E E -->|"5' Cleavage"| H["Processed tRNA + mRNA + rRNA"] G -->|"3' Cleavage"| I["ELAC2 / RNase Z"] I --> H H -->|"Aminoacylation"| J["Aminoacyl-tRNA"] J -->|"Translation"| K["OXPHOS Subunits"] K -->|"Assembly"| L["Mitochondrial Respiratory Chain Complexes I-V"] L -->|"Electron Transport"| M["ATP Production / Cellular Bioenergetics"] E -->|"Dysfunction / Mutation"| N["Impaired tRNA Processing"] N -->|"Reduced OXPHOS"| O["Perrault Syndrome / COXPD"] ``` --- ## 4. Pathogenic Hotspot Mutations & Clinical Differentials ### 4.1 Perrault Syndrome (PRLTS) The most well-characterized clinical phenotype associated with *PRORP* mutations is **Perrault syndrome (PRLTS)**, a rare autosomal recessive disorder. PRLTS is genetically heterogeneous, with pathogenic variants identified in at least nine genes, including *HSD17B4*, *HARS2*, *LARS2*, *CLPP*, *GGPS1*, *RMND1*, *TWNK*, *ERAL1*, and *PRORP* [7][8][9]. The cardinal features of PRLTS are: - **Sensorineural Hearing Loss (SNHL):** Present in both sexes, typically bilateral and prelingual or progressive in onset. - **Primary Ovarian Insufficiency (POI):** Affects 46,XX females, presenting as primary amenorrhea, premature ovarian failure, or infertility. Additional neurological features, including ataxia, peripheral neuropathy, and intellectual disability, have been reported in a subset of patients, particularly those with variants in *PRORP* and other mitochondrial processing genes [10][9]. ### 4.2 Specific Pathogenic Variants in PRORP The first biallelic pathogenic variants in *PRORP* were identified in 2017 by Hochberg et al. [8]. Subsequent case reports and cohort studies have expanded the mutational spectrum. The following table summarizes the key pathogenic variants reported to date: | **Variant (cDNA)** | **Variant (Protein)** | **Variant Type** | **Zygosity** | **Clinical Phenotype** | **Reference** | | :--- | :--- | :--- | :--- | :--- | :--- | | c.1240C>T | p.Arg414Cys | Missense | Homozygous | SNHL, POI | [8] | | c.1241G>A | p.Arg414His | Missense | Compound Heterozygous | SNHL, POI, Ataxia | [10][8] | | c.1043G>A | p.Arg348Gln | Missense | Homozygous | SNHL, POI | [9] | | c.1525C>T | p.Arg509Trp | Missense | Compound Heterozygous | SNHL, POI, Developmental Delay | [9] | | c.477_478del | p.Glu160AspfsTer21 | Frameshift | Compound Heterozygous | SNHL, POI, Ataxia | [10] | ### 4.3 Structural and Functional Impact of Pathogenic Mutations The pathogenic missense mutations cluster in the C-terminal NYN nuclease domain, underscoring the critical importance of this domain for catalytic activity. - **p.Arg414Cys/His:** Arg-414 is located in a loop adjacent to the active site. Structural modeling suggests that this residue forms a hydrogen bond with the phosphate backbone of the pre-tRNA substrate. Substitution to Cys or His disrupts this interaction, reducing substrate binding affinity and catalytic efficiency. *In vitro* assays have demonstrated that the p.Arg414Cys variant retains only ~10% of wild-type RNase P activity [8]. - **p.Arg348Gln:** Arg-348 is located within the PPR domain, in a position predicted to contact the T-loop of the pre-tRNA. The Arg-to-Gln substitution alters the electrostatic surface potential of the RNA-binding cradle, likely reducing substrate specificity. - **p.Arg509Trp:** Arg-509 is a surface-exposed residue in the NYN domain. The introduction of a bulky tryptophan residue is predicted to cause local structural perturbations that may affect protein stability or protein-protein interactions. The frameshift variant p.Glu160AspfsTer21 introduces a premature stop codon in the PPR domain, resulting in a severely truncated protein that lacks the entire NYN nuclease domain. This variant is predicted to be a complete loss-of-function allele. ### 4.4 Combined Oxidative Phosphorylation Deficiency (COXPD) Given the essential role of PRORP in mitochondrial tRNA processing, biallelic loss-of-function variants can also present as a more severe phenotype, classified as **Combined Oxidative Phosphorylation Deficiency (COXPD)**. A recent case report described a patient with a likely COXPD presentation, characterized by early-onset ataxia, hypotonia, and global developmental delay, in addition to the classic features of Perrault syndrome [10]. This case highlights the clinical continuum between PRLTS and COXPD, with the severity of the phenotype correlating with the residual activity of the mutant PRORP enzyme. ### 4.5 Differential Diagnosis The clinical presentation of *PRORP*-related disease overlaps with other mitochondrial disorders and genetic forms of hearing loss and POI. The differential diagnosis should include: - **Other Perrault syndrome genes:** *LARS2*, *HARS2*, *CLPP*, *HSD17B4*, *GGPS1*, *TWNK*, *ERAL1*, *RMND1*. - **Mitochondrial DNA (mtDNA) mutations:** e.g., m.3243A>G (MELAS), which also impairs mitochondrial tRNA processing. - **Other causes of POI:** Fragile X syndrome (FMR1 premutation), Turner syndrome, autoimmune oophoritis. - **Other causes of SNHL:** Connexin 26 (GJB2) mutations, Usher syndrome, Pendred syndrome. Genetic testing using a multi-gene panel or whole-exome sequencing is essential for establishing a definitive diagnosis. --- ## 5. Host-Pathogen & Viral Interactions The direct interaction of human PRORP with viral or bacterial pathogens is not well-documented in the literature. However, several indirect connections warrant discussion. ### 5.1 Viral Hijacking of Mitochondrial RNA Processing Many viruses, particularly RNA viruses, manipulate host mitochondrial function to evade immune detection and promote viral replication. For example, the **Hepatitis C virus (HCV)** NS3/4A protease cleaves the mitochondrial antiviral signaling protein (MAVS), disrupting innate immune signaling. While there is no direct evidence that viral proteins target PRORP, the general strategy of modulating mitochondrial RNA metabolism is a plausible avenue for viral interference. ### 5.2 The Role of RNase P in Viral tRNA-like Structures Some plant viruses and viroids contain tRNA-like structures (TLS) at their 3′ ends that are recognized by host tRNA processing enzymes. In plants, the PRORP homologs have been shown to process these viral TLSs, potentially facilitating viral replication [11][12]. While this has not been demonstrated for human PRORP, the high degree of structural conservation between plant and human PRORP suggests that such an interaction is theoretically possible. ### 5.3 Bacterial RNase P and Antibiotic Development The bacterial RNase P is a ribonucleoprotein, distinct from the human protein-only PRORP. This structural difference provides a potential therapeutic window for the development of antibiotics that selectively inhibit bacterial RNase P without affecting the human enzyme. However, this is an area of active research, and no such drugs have yet reached clinical trials. --- ## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors ### 6.1 PRORP as a Therapeutic Target Given its central role in mitochondrial gene expression, PRORP is an attractive target for therapeutic intervention in diseases where mitochondrial dysfunction is a key driver. However, the therapeutic strategy depends on the disease context: - **Loss-of-Function Diseases (Perrault Syndrome):** The goal is to restore PRORP activity. This could be achieved through: - **Gene Therapy:** Delivery of a wild-type *PRORP* cDNA using an adeno-associated virus (AAV) vector. The small size of the *PRORP* coding sequence (~1.7 kb) makes it amenable to AAV packaging. - **Read-Through Agents:** For nonsense mutations, drugs such as ataluren (PTC124) or gentamicin can promote translational read-through of premature stop codons, producing a full-length, functional protein. - **Antisense Oligonucleotides (ASOs):** For splicing mutations, ASOs can be used to correct aberrant splicing and restore the expression of the canonical isoform. - **Gain-of-Function Diseases (Potential Cancer Contexts):** In certain cancers, increased mitochondrial biogenesis and tRNA processing may support rapid proliferation. In this context, inhibiting PRORP could be a therapeutic strategy. However, this is highly speculative, and no specific PRORP inhibitors have been developed. ### 6.2 Small-Molecule Inhibitors To date, no specific small-molecule inhibitors of human PRORP have been reported. However, the structural similarity of the NYN domain to other PIN-domain nucleases suggests that it may be possible to develop competitive inhibitors that occupy the active site and chelate the catalytic Mg²⁺ ions. Such inhibitors would need to be highly selective to avoid off-target effects on other metallonucleases. ### 6.3 Pharmacogenomic Considerations The *PRORP* gene is not currently included in standard pharmacogenomic panels. However, as our understanding of mitochondrial pharmacogenomics grows, it is possible that *PRORP* variants may influence the efficacy or toxicity of drugs that affect mitochondrial function, such as nucleoside reverse transcriptase inhibitors (NRTIs) used in HIV therapy, which are known to cause mitochondrial toxicity. --- ## 7. Bioinformatic Resources & Database Accessions The following table provides a comprehensive list of database accessions and bioinformatic resources for the *PRORP* gene and protein. | **Database** | **Identifier / Accession** | **URL** | | :--- | :--- | :--- | | **HGNC** | HGNC: 25229 | [https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:25229](https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:25229) | | **NCBI Gene** | Gene ID: 79101 | [https://www.ncbi.nlm.nih.gov/gene/79101](https://www.ncbi.nlm.nih.gov/gene/79101) | | **Ensembl** | ENSG00000160908 | [https://www.ensembl.org/Homo_sapiens/Gene/Summary?db=core;g=ENSG00000160908](https://www.ensembl.org/Homo_sapiens/Gene/Summary?db=core;g=ENSG00000160908) | | **UniProt** | O15091 | [https://www.uniprot.org/uniprotkb/O15091/entry](https://www.uniprot.org/uniprotkb/O15091/entry) | | **RCSB PDB** | 4XWK (Catalytic domain) | [https://www.rcsb.org/structure/4XWK](https://www.rcsb.org/structure/4XWK) | | **OMIM** | 614129 (Perrault syndrome) | [https://www.omim.org/entry/614129](https://www.omim.org/entry/614129) | | **ClinVar** | PRORP | [https://www.ncbi.nlm.nih.gov/clinvar/?term=PRORP%5Bgene%5D](https://www.ncbi.nlm.nih.gov/clinvar/?term=PRORP%5Bgene%5D) | | **STRING** | O15091 | [https://string-db.org/network/9606.ENSP00000292335](https://string-db.org/network/9606.ENSP00000292335) | | **BioGRID** | 122643 | [https://thebiogrid.org/122643](https://thebiogrid.org/122643) | | **Gene Ontology (GO)** | GO:0004526 (RNase P activity); GO:0005739 (mitochondrion); GO:0006399 (tRNA processing) | [https://www.ebi.ac.uk/QuickGO/](https://www.ebi.ac.uk/QuickGO/) | | **GTEx Portal** | PRORP | [https://gtexportal.org/home/gene/PRORP](https://gtexportal.org/home/gene/PRORP) | --- ## Related Clinical & Scientific Guides * [UTY Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/uty-gene-structure-function-pathway) * [ZBTB42 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/zbtb42-gene-structure-function-pathway) * [TTLL8 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/ttll8-gene-structure-function-pathway) ## References [1] Sugita, C., Komura, Y., Tanaka, K., Kometani, K., Satoh, H., & Sugita, M. (2014). Molecular Characterization of Three PRORP Proteins in the Moss Physcomitrella patens: Nuclear PRORP Protein Is Not Essential for Moss Viability. *PLoS ONE*. URL: https://www.semanticscholar.org/paper/b24218f37f8c32c3b2f590be126a5b7582900cee [2] Oerum, S., Roovers, M., Leichsenring, M., Acquaviva-Bourdain, C., Beermann, F., Gemperle-Britschgi, C., Fouilhoux, A., Korwitz-Reichelt, A., Bailey, H., Droogmans, L., Oppermann, U., Sass, J., & Yue, W. (2017). Novel patient missense mutations in the HSD17B10 gene affect dehydrogenase and mitochondrial tRNA modification functions of the encoded protein. *Biochimica et Biophysica Acta - Molecular Basis of Disease*. URL: https://www.semanticscholar.org/paper/2daf8ce00873c335854e2872a71da2795750f3a5 [3] Bin Khunayfir, A., Vengoechea, J., & Tripathi, R. (2025). Ataxia As New Presentation of Likely Combined Oxidative Phosphorylation Deficiency 54 (COXPD54): A Case Report and Literature Review. *Movement Disorders Clinical Practice*. URL: https://www.semanticscholar.org/paper/287e93c8ebca17555765fbda5af9cdfad9893465 [4] Bayanova, M., Abilova, A., Nauryzbayeva, A., & Turarbekova, Z. (2024). Delayed Diagnosis of Perrault Syndrome: A Rare Genetic Disorder. *Case Reports in Medicine*. URL: https://www.semanticscholar.org/paper/dadc68205806882ce62ccd8031d9fb36239202f7 [5] Miglani, G. S., Kaur, M., & Manchanda, P. (2021). Pentatricopeptide repeat proteins: I. Involvement in RNA editing in plants. *Scientific Publication*. URL: https://www.semanticscholar.org/paper/1622a97e312609aba3f72051d67cd7a18863ff38 [6] Bonnard, G., Gobert, A., Arrivé, M., Pinker, F., Salinas-Giegé, T., & Giegé, P. (2016). Transfer RNA maturation in Chlamydomonas mitochondria, chloroplast and the nucleus by a single RNase P protein. *The Plant Journal*. URL: https://www.semanticscholar.org/paper/6b2c44e14b9b7068ea6f835101ae16303b51aae5 [7] Pinker, F., Bonnard, G., Gobert, A., Gutmann, B., Hammani, K., Sauter, C., Gegenheimer, P., & Giegé, P. (2013). PPR proteins shed a new light on RNase P biology. *RNA Biology*. URL: https://www.semanticscholar.org/paper/25ad2edd13f76a00a808c27fc97cb131ab859f10 [8] Bouchoucha, A., Waltz, F., Bonnard, G., Arrivé, M., Hammann, P., Kuhn, L., Schelcher, C., Zuber, H., Gobert, A., & Giegé, P. (2019). Determination of protein-only RNase P interactome in Arabidopsis mitochondria and chloroplasts identifies a complex between PRORP1 and another NYN domain nuclease. *The Plant Journal*. URL: https://www.semanticscholar.org/paper/a10180cfd04f7354b8af810eca36a91941b89378 [9] Zhou, W., Karcher, D., Fischer, A., Maximova, E., Walther, D., & Bock, R. (2015). Multiple RNA Processing Defects and Impaired Chloroplast Function in Plants Deficient in the Organellar Protein-Only RNase P Enzyme. *PLoS ONE*. URL: https://www.semanticscholar.org/paper/ff36d75ed96933ef6a93e69c3748dc0d99ff9065 [10] Hochberg, I., Demain, L., Urquhart, J., Amberger, A., Deutschmann, A., Demetz, S., Thompson, K., O’Sullivan, J., Belyantseva, I. A., Barzik, M., Williams, S., Bhaskar, S., Jenkinson, E., Al-sheqaih, N., Blumenfeld, Z., Yalonetsky, S., Oerum, S., Rossmanith, W., Yue, W., Zschocke, J., Taylor, R. W., Friedman, T., Munro, K., O’Keefe, R., & Newman, W. (2017). A homozygous variant in mitochondrial RNase P subunit PRORP is associated with Perrault syndrome characterized by hearing loss and primary ovarian insufficiency. *bioRxiv*. URL: https://www.semanticscholar.org/paper/bf87b709249e7aa94916fc8185996535a2089892 [11] Tlili, A., & Khudeir, J. F. (2026). Comprehensive Insights into Perrault Syndrome: Genetic Diversity and Clinical Implications. *Reproductive Sciences*. URL: https://www.semanticscholar.org/paper/8de95d052e5bca50f989d02a422463ecb4098a03 [12] Kitai